Company Overview and News
Benitec Biopharma Ltd’s (ASX:BLT) shares closed 20% higher on Wednesday after securing a new patent related to its hepatitis B program in the U.S.
If you want a Stock Review on BDSI, BLRX, BNTC or SNGX then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has initiated coverage on BioDelivery Sciences International Inc. (NASDAQ: BDSI), BioLine Rx Ltd (NASDAQ: BLRX), Benitec Biopharma Ltd (NASDAQ: BNTC), and Soligenix Inc. (NASDAQ: SNGX). These equities operate in the Biotech space, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures.
WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017. (0-1)
Thank you for standing by and welcome to the Benitec Biopharma Quarterly Corporate Update Conference Call.
On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Biotechnology equities this morning: Cymabay Therapeutics Inc. (NASDAQ: CBAY), Benitec Biopharma Ltd (NASDAQ: BNTC), Sage Therapeutics Inc.
On Tuesday, April 25, 2017, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,025.49, up 0.70%; the Dow Jones Industrial Average edged 1.12% higher, to finish at 20,996.12; and the S&P 500 closed at 2,388.61, up 0.61%. This Wednesday morning, Stock-Callers.
Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that it has appointed Mr Iain Ross as Chairman of its Board of Directors and as a Non-Executive Director of the Company, effective from 1st May 2017.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
LONDON, April 4 Global investment banking fees reached a 10-year high in the first quarter of 2017 with more than half of the $24 billion in total takings coming from North America, Thomson Reuters data showed on Tuesday.
* Solar Alliance Energy - as per loi, co will acquire seller's team of employees and acquire seller's pipeline of in-process residential solar projects
* Benitec Biopharma Ltd - key pre-clinical data on oculopharyngeal muscular dystrophy (opmd) published in nature communications
Benitec Biopharma (ASX:BLT) has received a $5.59 million cash refund under the Federal Government’s R&D Tax Incentive Scheme.
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Benitec Biopharma Ltd. (NASDAQ: BNTC) saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases. Specifically Benitec noted that the output from its collaboration with 4D Molecular Therapeutics has been instrumental in the treatment’s development. Although this update does seem vague at first glance, the company appears to be planning a firework for an upcoming convention.
Bioblast Pharma Ltd. (ORPN - Free Report) announced positive results from a phase IIa study on its lead candidate, trehalose, for the treatment of patients with spinocerebellar ataxia type 3 (SCA3). A look at Bioblast’s price movement during the past one year shows that the company has underperformed the Medical Drugs industry. Specifically, the stock lost 57.9%, while the industry fell 11.2%.
NEW YORK, NY / ACCESSWIRE / January 18, 2017 / Biotech and Pharmaceutical companies took a hit last week after President Trump criticized the drug industry at a press conference.
Shares of Benitec Biopharma Limited surged 62.2% after the company announced that its proposed candidate, BB-301, has received Orphan Drug Designation in the EU for the treatment of patients with ocularpharyngeal muscular dystrophy (OPMD). A look at Benitec’s price movement in the past one year shows that the company has underperformed the Medical-Biomedical/Genetics industry. Specifically, the stock declined 23.
The European Commission designates Benitec Biopharma's (NASDAQ:BNTC) BB-301 an Orphan Drug for the treatment of oculopharyngeal muscular dystrophy (OPMD), an inherited disorder characterized by muscle weakness, specifically droopy eyelids and difficulty swallowing.
Some biotech and pharma companies were on the move Tuesday. A few of the smaller caps made tremendous gains on the day, as the fourth-quarter earnings season is kicking off. Although some of these companies may not be the largest in the sector, they still posted the largest gains or losses on the day.
OPMD is a rare inherited myopathy characterised by dysphagia (difficulty in swallowing), the loss of muscle strength, and weakness in multiple parts of the body.
Benitec Biopharma (NASDAQ:BNTC) enters into a global sublicensing agreement with NantWorks to develop a clinical stage product candidate to treat head and neck squamous cell carcinoma (HNSCC) using a gene silencing approach targeting the epidermal growth factor receptor (EGFR).
- Returns Benitec to clinical stage company - Clinical proof of concept achieved via demonstration of durable anti-tumor activity in advanced head and neck cancer patients - Continued development under planned research collaboration with NantWorks
- Significant and sustained drop of serum HBV DNA levels, HBsAg levels and HBeAg levels with BB-103 and BB-102 in combination with current standard of care agents - Supports continued progression of lead product candidate towards the clinic
ReportsnReports.com adds "Muscular Dystrophy - Pipeline Review, H2 2016" to its store, providing comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The company’s strategy is to make active investments in life science businesses and late-stage product development opportunities that will benefit from greater access to development capital. The new partnership is aimed at identifying and facilitating a range of new business opportunities with biotech and medtech companies on both sides of the Pacific. Dr. John Chiplin currently serves on the boards of Adalta, Batu Biologics, Benitec Biopharma, The Coma Research Institute and Sienna Cancer Diagnostics among others.
3h - Asif
18h - Asif